Janssen Sciences Ireland Uc

Janssen R&d Ireland

Janssen Research & Development Ireland

Samuel Dominique Demin

Ludwig Paul Cooymans

Pierre Jean-Marie Raboisson

Tim Hugo Jonckers

Sandrine Marie Vendeville

Pierre Jean-Marie Bernard Raboisson

David Craig McGowan

Stefaan Julien Last

Tim Hugo Maria Jonckers

Abdellah Tahri

Koen Vandyck

Sandrine Marie Helene Vendeville

Lili Hu

Quinoxalinones and dihydroquinoxalinones having inhibitory activity on RSV replication and having the formula I including addition salts, and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents

The present invention is concerned with novel 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof,wherein R, R, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents

Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R* have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in the treatment or prophylaxis of HCV.

Phenyl ethynyl derivatives as hepatitis C virus inhibitors

Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.

Bis-benzimidazole derivatives as hepatitis C virus inhibitors

Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.

Diaryl ethers

Growing community of inventors

Mechelen, Belgium

Samuel Dominique Demin